TrialLancet (London, England)2017

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Achim Rittmeyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.